Boehringer Ingelheim extends deal with Medidata for trial tech
Boehringer Ingelheim has renewed its agreement with Medidata, opting to use the trial tech firm’s electronic data capture systems for drug research for another five years.
The deal extension – financial terms of which were not disclosed – covers Boehringer’s use of the EDC system as well as a web-based platform that provides access to electronic consent, electronic Clinical Outcome Assessment (eCOA).
The German drug company is also exploring Medidata’s AI intelligent trials technology in a bid to “to improve the speed, success, and quality of clinical trials.”
Clinical program
Boehringer Ingelheim current program of clinical trials is extensive and likely to expand over the next five years.
According to its 2021 report the firm’s R&D investments in Human Pharma rose to €3.7 billion up from €3.3 billion it spent the year earlier.
“The R&D pipeline in Human Pharma comprises more than 100 clinical and preclinical projects. Based on the progress of the later stage projects, the pipeline has the potential to deliver up to 15 new product launches until 2025.”
The firm also reported “significant” progress in its late-stage drug pipeline, adding that “For the next five years, plans are to invest over 25 billion EUR in its research pipeline.
Boehringer Ingelheim and Medidata have worked together since 2015 when the former licensed access to the latter’s clinical cloud technology.
R&D software demand
Boehringer Ingelheim’s plan to increase R&D investment are in keeping with trends discussed by Medidata’s owner Dassault Systèmes during its third quarter results presentation in October.
According to the firm life sciences software revenue rose 14% IFRS and 13% on a non-IFRS basis, to €294.6 million, representing 24% of software revenue.
Dassault cited Medidata – and more specifically its partnerships with drug firms and CROs – as key to this revenue growth.
“Medidata continued to deliver strong performance driven by broad-based growth across product lines and end-markets. Life sciences companies are prioritizing R&D investments and with a renewed focus on value.”
DepositPhotos/iqoncept